Short answer
Nuvalent, Inc. (NUVL) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$122M
- −45.2% YoY · −22.9% QoQ
- EPS (diluted)
- −$1.70
- −31.8% YoY · −22.3% QoQ
Source: XBRL data from the Nuvalent, Inc. (NUVL) Q3 2025 10-Q on SEC EDGAR. USD.
Nuvalent, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Need for capital beyond current cash runway into 2028 triggered by advancing zidesamtinib, neladalkib, NVL-330, and discovery programs
- Updated risk: Net losses increased to $306.7M for nine months ended Sept 30, 2025, vs $260.8M for 2024, reflecting higher R&D and commercialization prep costs
- Regulatory risk: FDA or EMA requiring additional clinical trials or data before marketing approval, delaying product launch and increasing costs
- Operational risk: Clinical trial delays or suspensions from patient enrollment challenges, adverse events, or CRO non-compliance impacting development timelines
- Financial risk: No committed external funding; potential dilution or restrictive covenants from future equity or debt financing essential to fund ops beyond current cash
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nuvalent, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.